Archivos De Bronconeumologia最新文献

英文中文

A New Horizon for an Old Disease: Modern Strategies for Approaching Chronic Cough 一种古老疾病的新视野：治疗慢性咳嗽的现代策略。

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/j.arbres.2025.07.020

Christian Domingo , Astrid Crespo-Lessmann , Lorcan McGarvey

引用次数: 0

CO1 CO1

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/S0300-2896(25)00420-X

引用次数: 0

SEPAR Position Paper on the Use of High Flow Nasal Cannula Therapy in the Home Setting SEPAR关于在家庭环境中使用高流量鼻插管治疗的立场文件。

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/j.arbres.2025.04.010

Raúl Moreno-Zabaleta , Manel Luján Torne , Javier Sayas Catalán , Pedro García Torres , Daniel López Padilla , Mar Mosteiro Añón , Sergi Martí Beltrán , Ascensión Hernando Sanz , Mónica González Martínez , Olga Mediano

The purpose of this document is to establish SEPAR's official position on the use of high-flow nasal cannula (HFNC) therapy in the home management of patients with chronic respiratory diseases. This position statement is deemed necessary considering current evidence regarding HFNC use in chronic respiratory conditions, with the objective of standardizing its application. This consensus was developed by a panel of experts comprising specialists with established expertise in chronic respiratory failure and high-flow nasal cannula therapy. The panel of experts stablished recommendations in COPD, bronchiectasis, interstitial lung diseases, palliative care, rehabilitation, and chronic treatment settings.

本文件的目的是确立SEPAR在慢性呼吸系统疾病患者家庭管理中使用高流量鼻插管（HFNC）治疗的官方立场。考虑到目前关于HFNC用于慢性呼吸系统疾病的证据，本立场声明被认为是必要的，目的是使其应用标准化。这一共识是由一个专家小组制定的，其中包括在慢性呼吸衰竭和高流量鼻插管治疗方面具有既定专业知识的专家。专家小组制定了COPD、支气管扩张、间质性肺疾病、姑息治疗、康复和慢性治疗环境方面的建议。

引用次数: 0

Lung Diffusing Capacity Improves the Prognostic Validity of the GOLD Spirometric Staging in COPD 肺弥散能力提高COPD GOLD肺量分期的预后有效性。

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/j.arbres.2025.05.004

Ciro Casanova , Enrique Gonzalez-Dávila , Juan P. de Torres , Carlos Cabrera , Borja G. Cosio , Denis E. O’Donnel , Cristina Martínez-Gonzalez , Ingrid Solanes , Antonia Fuster , Carolina Gotera , Alicia Marin , Carlos Amado , Marta Iscar , José M. Marin , José Alberto Neder , Nuria Feu , Joan B. Soriano , José Luis López-Campos , Miguel Divo , Germán Peces-Barba , Bartolomé R. Celli

Rationale

The lung diffusing capacity for carbon monoxide (DLco), a metric of gas transfer, provides physiological information distinct from spirometry. While DLco independently predicts mortality in COPD, its integration into the GOLD spirometric staging (% FEV₁) to improve risk assessment, remains unexplored.

Objectives

To determine if DLco enhances the predictive power of GOLD spirometric classification for all-cause and respiratory mortality.

Methods

We followed 469 patients (mean age 64 years, 58% FEV₁) with complete lung function tests in the Spanish multicenter CHAIN study for up to 10 years, with mortality as the main outcome. Patients were dichotomized based on DLco impairment (<50% cutoff). A Cox proportional hazard model evaluated the added value of DLco to GOLD FEV₁ spirometric staging for all-cause and respiratory mortality. Validation of the results was conducted in the Kingston COPD Canadian cohort (N = 300 patients).

Results

Over time, 184 (39.2%) patients died, 84 (17.9%) from respiratory causes. Adjusted analyses showed DLco < 50% independently predicted all-cause [HR = 1.83 (95%CI 1.32–2.54, p < 0.001)] and respiratory [HR = 2.27 (95%CI 1.43–3.60, p < 0.001)] mortality. Incorporating DLco < 50% increased mortality risk compared to FEV₁ alone, particularly in GOLD stages 3 and 4, where survival time decreased by 1.23 years (p = 0.002) and 1.25 years (p = 0.004) for all-cause and respiratory deaths, respectively. These findings were validated in the Canadian cohort.

Conclusions

Adding DLco to FEV₁ enhances the prognostic accuracy of the GOLD spirometric severity classification, especially for patients in GOLD stages 3–4 at higher risk of adverse outcomes.

ClinicalTrials.gov Identifier: NCT01122758.

原理：肺一氧化碳弥散量（DLco）是一种气体传递的度量，它提供了不同于肺活量测定法的生理信息。虽然DLco可以独立预测COPD的死亡率，但其与GOLD肺量分期（% FEV1）的整合以改善风险评估仍未得到探索。目的：确定DLco是否能增强GOLD肺量分级对全因死亡率和呼吸系统死亡率的预测能力。方法：我们在西班牙多中心CHAIN研究中对469例患者（平均年龄64岁，58% FEV1）进行了长达10年的完整肺功能检查，以死亡率为主要结果。根据全因死亡率和呼吸死亡率的DLco损伤(1)肺活量分期对患者进行二分类。在Kingston COPD加拿大队列（N=300例患者）中对结果进行了验证。结果：随时间推移，184例（39.2%）患者死亡，84例（17.9%）患者死于呼吸系统疾病。调整后的分析显示，DLco1单独存在，特别是在GOLD的3期和4期，全因死亡和呼吸系统死亡的生存时间分别减少1.23年（p=0.002）和1.25年（p=0.004）。这些发现在加拿大队列中得到了验证。结论：在FEV1中加入DLco可提高GOLD肺量严重程度分级的预后准确性，特别是对于不良结局风险较高的GOLD 3-4期患者。临床试验：gov标识符：NCT01122758。

{"title":"Lung Diffusing Capacity Improves the Prognostic Validity of the GOLD Spirometric Staging in COPD","authors":"Ciro Casanova , Enrique Gonzalez-Dávila , Juan P. de Torres , Carlos Cabrera , Borja G. Cosio , Denis E. O’Donnel , Cristina Martínez-Gonzalez , Ingrid Solanes , Antonia Fuster , Carolina Gotera , Alicia Marin , Carlos Amado , Marta Iscar , José M. Marin , José Alberto Neder , Nuria Feu , Joan B. Soriano , José Luis López-Campos , Miguel Divo , Germán Peces-Barba , Bartolomé R. Celli","doi":"10.1016/j.arbres.2025.05.004","DOIUrl":"10.1016/j.arbres.2025.05.004","url":null,"abstract":"<div><h3>Rationale</h3><div><span><span><span><span>The lung diffusing capacity for </span>carbon monoxide (DLco), a metric of </span>gas transfer<span>, provides physiological information distinct from spirometry. While DLco independently predicts mortality in </span></span>COPD<span>, its integration into the GOLD spirometric staging (% FEV</span></span><sub>1</sub>) to improve risk assessment, remains unexplored.</div></div><div><h3>Objectives</h3><div>To determine if DLco enhances the predictive power of GOLD spirometric classification for all-cause and respiratory mortality.</div></div><div><h3>Methods</h3><div>We followed 469 patients (mean age 64 years, 58% FEV<sub>1</sub><span><span><span>) with complete lung function tests in the Spanish multicenter </span>CHAIN study for up to 10 years, with mortality as the main outcome. Patients were dichotomized based on DLco impairment (<50% cutoff). A Cox </span>proportional hazard model evaluated the added value of DLco to GOLD FEV</span><sub>1</sub><span> spirometric staging for all-cause and respiratory mortality. Validation of the results was conducted in the Kingston COPD Canadian cohort (</span><em>N</em>      <0.001)] and respiratory [HR=2.27 (95%CI 1.43–3.60, <em>p</em>    =0.002) and 1.25 years (<em>p</em>  <!-->0.004) for all-cause and respiratory deaths, respectively. These findings were validated in the Canadian cohort.</div></div><div><h3>Conclusions</h3><div>Adding DLco to FEV<sub>1</sub><span> enhances the prognostic accuracy of the GOLD spirometric severity classification, especially for patients in GOLD stages 3–4 at higher risk of adverse outcomes.</span></div><div>ClinicalTrials.gov Identifier: <span><span>NCT01122758</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 20-27"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Possible Association Between Galcanezumab and Pulmonary Arterial Hypertension Galcanezumab与肺动脉高压的可能关联

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/j.arbres.2025.07.023

Alejandro Cruz-Utrilla , Daniel Toledo-Alfocea , Pilar Escribano-Subias

引用次数: 0

Pulmonary Adiaspiromycosis in humans: an updated review of a rare mycosis 人类肺硬螺旋体真菌病：一种罕见真菌病的最新综述。

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/j.arbres.2025.08.011

Ángel Cilleruelo-Ramos , María Isabel Ramos-Cancelo , Álvaro Pérez-Rodríguez

引用次数: 0

Airway Stenting for Endothoracic Goiter 气管支架置入术治疗胸内甲状腺肿。

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/j.arbres.2025.07.010

Toni Marín, Pedro J. Rodríguez, Rachid Tazi

引用次数: 0

Impaired Ventilatory Efficiency Identifies High-Risk Mild-to-Moderate Chronic Obstructive Pulmonary Disease 通气效率受损可识别高危轻至中度慢性阻塞性肺疾病。

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/j.arbres.2025.04.005

Zhishan Deng , Fan Wu , Qi Wan , Cuiqiong Dai , Lifei Lu , Zihui Wang , Kunning Zhou , Xiaohui Wu , Gaoying Tang , Huajing Yang , Jieqi Peng , Suyin Huang , Guannan Cai , Fangyan Wu , Junfeng Lin , Xiaoyu Wang , Changli Yang , Yongqing Huang , Rongchang Chen , Nanshan Zhong , Pixin Ran

Objectives

Identifying high-risk patients is fundamental to slowing disease progression in mild-to-moderate COPD. Over one-fifth of these patients have impaired ventilatory efficiency, strongly associated with advanced disease severity, while its unclear prognostic value for high-risk case identification persists.

Methods

This was a prospective cohort study conducted from July 2019 to September 2024 (encompassing the COVID-19 pandemic period) in China. Non-COPD subjects and mild-to-moderate COPD patients who completed questionnaires, lung function tests and cardiopulmonary exercise tests at baseline were annually followed up over 3 years. Subjects with predefined high-risk criteria, including CAT score ≥ 10, mMRC score ≥ 2, postbronchodilator FEV₁ < 60% predicted, and frequent exacerbations, were further excluded. Impaired ventilatory efficiency was defined as a nadir minute ventilation/CO₂ output ≥ the upper limit of normal. Outcomes included annual lung function decline, exacerbation risks, and symptom scores.

Results

A total of 780 subjects were included, with 684 (88%) completing follow-up. Patients with impaired ventilatory efficiency displayed a greater annual decline in postbronchodilator FEV₁ (54 [95% CI: 32–76] mL/year) than patients with normal ventilatory efficiency (31 [15–47] mL/year, adjusted P = 0.008) and non-COPD subjects (31 [22–40] mL/year, adjusted P = 0.001). However, no significant difference existed between patients with normal ventilatory efficiency and non-COPD subjects (adjusted P = 0.756). Similar results were observed for exacerbation risks and symptom scores.

Conclusions

Impaired ventilatory efficiency can identify high-risk mild-to-moderate COPD patients with poor prognosis independently of established risk factors. Further studies are needed to explore effective interventions for patients with impaired ventilatory efficiency.

目的：识别高危患者是减缓轻至中度COPD疾病进展的基础。超过五分之一的患者通气效率受损，与疾病严重程度密切相关，但其对高风险病例识别的预后价值仍不明确。方法：这是一项2019年7月至2024年9月（包括COVID-19大流行期）在中国进行的前瞻性队列研究。非COPD受试者和轻至中度COPD患者在基线时完成问卷调查、肺功能测试和心肺运动测试，每年随访3年以上。受试者具有预定义的高危标准，包括CAT评分≥10分，mMRC评分≥2分，支气管扩张剂后FEV12输出≥正常上限。结果包括年度肺功能下降、恶化风险和症状评分。结果：共纳入780例受试者，684例（88%）完成随访。通气效率受损患者支气管扩张剂后FEV1的年下降幅度（54 [95% CI: 32-76]mL/年）大于通气效率正常患者（31 [15-47]mL/年，调整P=0.008）和非copd患者（31 [22-40]mL/年，调整P=0.001）。而正常通气效率患者与非copd患者间无显著性差异（P=0.756）。在加重风险和症状评分方面也观察到类似的结果。结论：通气效率受损可独立于已确定的危险因素识别预后不良的轻中度COPD高危患者。需要进一步的研究来探索对通气效率受损患者的有效干预措施。

{"title":"Impaired Ventilatory Efficiency Identifies High-Risk Mild-to-Moderate Chronic Obstructive Pulmonary Disease","authors":"Zhishan Deng , Fan Wu , Qi Wan , Cuiqiong Dai , Lifei Lu , Zihui Wang , Kunning Zhou , Xiaohui Wu , Gaoying Tang , Huajing Yang , Jieqi Peng , Suyin Huang , Guannan Cai , Fangyan Wu , Junfeng Lin , Xiaoyu Wang , Changli Yang , Yongqing Huang , Rongchang Chen , Nanshan Zhong , Pixin Ran","doi":"10.1016/j.arbres.2025.04.005","DOIUrl":"10.1016/j.arbres.2025.04.005","url":null,"abstract":"<div><h3>Objectives</h3><div>Identifying high-risk patients is fundamental to slowing disease progression<span> in mild-to-moderate COPD. Over one-fifth of these patients have impaired ventilatory efficiency, strongly associated with advanced disease severity, while its unclear prognostic value for high-risk case identification persists.</span></div></div><div><h3>Methods</h3><div><span>This was a prospective cohort study<span><span> conducted from July 2019 to September 2024 (encompassing the COVID-19 pandemic period) in China. Non-COPD subjects and mild-to-moderate COPD<span> patients who completed questionnaires, lung function tests and </span></span>cardiopulmonary exercise tests at baseline were annually followed up over 3 years. Subjects with predefined high-risk criteria, including CAT score</span></span>  <span>10, mMRC score</span>  <60% predicted, and frequent exacerbations, were further excluded. Impaired ventilatory efficiency was defined as a nadir minute ventilation/CO<sub>2</sub> output≥the upper limit of normal. Outcomes included annual lung function decline, exacerbation risks, and symptom scores.</div></div><div><h3>Results</h3><div>A total of 780 subjects were included, with 684 (88%) completing follow-up. Patients with impaired ventilatory efficiency displayed a greater annual decline in postbronchodilator FEV<sub>1</sub> (54 [95% CI: 32–76]mL/year) than patients with normal ventilatory efficiency (31 [15–47] mL/year, adjusted <em>P</em>   =0.001). However, no significant difference existed between patients with normal ventilatory efficiency and non-COPD subjects (adjusted <em>P</em>  <!-->0.756). Similar results were observed for exacerbation risks and symptom scores.</div></div><div><h3>Conclusions</h3><div>Impaired ventilatory efficiency can identify high-risk mild-to-moderate COPD patients with poor prognosis independently of established risk factors. Further studies are needed to explore effective interventions for patients with impaired ventilatory efficiency.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 10-19"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk validation of a new quantitative score for clinical control of chronic obstructive pulmonary disease: The RADAR score 一种新的慢性阻塞性肺疾病临床控制定量评分的风险验证：RADAR评分。

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2026-01-01 DOI: 10.1016/j.arbres.2025.06.003

Juan José Soler-Cataluña , María Villagrasa , Pablo Catalán , Bernardino Alcázar-Navarrete , Myriam Calle Rubio , Marc Miravitlles

Objective

Clinical control has been proposed as a composite endpoint in chronic obstructive pulmonary disease (COPD), assessable through the COPD Clinical Control Questionnaire (CCOq). A new score, derived from the CCOq, and termed as RADAR (Rescue medication, Acute exacerbations, Dyspnea, physical Activity, and Risk) has been developed. This study aimed to validate the RADAR score by analyzing its predictive value for future risk and health status.

Methods

A 12-month prospective observational study was conducted in stable COPD patients. Clinical control was assessed at 3 months using both the CCOq and the RADAR score (range 0–8). Dyspnea was evaluated both adjusted and unadjusted for FEV₁%. The primary outcome was time to the first composite event (emergency visit, COPD hospitalization, or all-cause mortality); the secondary outcome was the COPD Assessment Test (CAT) score at 12 months.

Results

Of 265 patients enrolled (16.2% women; mean age: 68 ± 9 years; FEV₁%: 58 ± 17), 239 completed the 3-month assessment. Among patients with RADAR scores of 0–1, 96.5% met CCOq control criteria, whereas none with scores ≥4 were classified as controlled. Patients were categorized as good (0–1), partial (2–3), or poor control (≥4). Time to composite event differed significantly across groups (p < 0.001), with RADAR remaining an independent predictor after adjustment. Predictive accuracy (C-statistic) was 0.697 (adjusted) and 0.713 (unadjusted).

Conclusion

The RADAR score effectively predicts clinical risk and health status, offering a practical tool for monitoring COPD and guiding clinical decisions.

目的：临床控制已被提出作为慢性阻塞性肺疾病（COPD）的一个复合终点，可通过COPD临床控制问卷（CCOq）进行评估。从CCOq衍生出一种新的评分方法，称为RADAR（急救用药、急性加重、呼吸困难、体力活动和风险）。本研究旨在通过分析RADAR评分对未来风险和健康状况的预测价值来验证其有效性。方法：对稳定期COPD患者进行为期12个月的前瞻性观察研究。临床对照在3个月时使用CCOq和RADAR评分（范围0-8）进行评估。在FEV1%调整和未调整时评估呼吸困难。主要终点是发生第一次复合事件（急诊就诊、COPD住院或全因死亡率）的时间；次要终点是12个月时COPD评估测试（CAT）评分。结果：265例入组患者中(16.2%为女性；平均年龄：68±9岁；FEV1%: 58±17)，239例完成3个月评估。RADAR评分为0 ~ 1分的患者中，96.5%的患者符合CCOq控制标准，而评分≥4分的患者均未被归为对照。患者分为良好（0-1）、部分（2-3）和控制不良（≥4）。结论：RADAR评分可有效预测临床风险和健康状况，为COPD监测和指导临床决策提供实用工具。

{"title":"Risk validation of a new quantitative score for clinical control of chronic obstructive pulmonary disease: The RADAR score","authors":"Juan José Soler-Cataluña , María Villagrasa , Pablo Catalán , Bernardino Alcázar-Navarrete , Myriam Calle Rubio , Marc Miravitlles","doi":"10.1016/j.arbres.2025.06.003","DOIUrl":"10.1016/j.arbres.2025.06.003","url":null,"abstract":"<div><h3>Objective</h3><div>Clinical control has been proposed as a composite endpoint in chronic obstructive pulmonary disease<span> (COPD), assessable through the COPD Clinical Control Questionnaire (CCOq). A new score, derived from the CCOq, and termed as RADAR (Rescue medication, Acute exacerbations, Dyspnea, physical Activity<span>, and Risk) has been developed. This study aimed to validate the RADAR score by analyzing its predictive value for future risk and health status.</span></span></div></div><div><h3>Methods</h3><div>A 12-month prospective observational study was conducted in stable COPD patients. Clinical control was assessed at 3 months using both the CCOq and the RADAR score (range 0–8). Dyspnea was evaluated both adjusted and unadjusted for FEV<sub>1</sub>%. The primary outcome was time to the first composite event (emergency visit, COPD hospitalization, or all-cause mortality); the secondary outcome was the COPD Assessment Test (CAT) score at 12 months.</div></div><div><h3>Results</h3><div>Of 265 patients enrolled (16.2% women; mean age: 68±9 years; FEV<sub>1</sub>%: 58±17), 239 completed the 3-month assessment. Among patients with RADAR scores of 0–1, 96.5% met CCOq control criteria, whereas none with scores ≥4 were classified as controlled. Patients were categorized as good (0–1), partial (2–3), or poor control (≥4). Time to composite event differed significantly across groups (<em>p</em>  <!-->0.001), with RADAR remaining an independent predictor after adjustment. Predictive accuracy (<em>C</em>-statistic) was 0.697 (adjusted) and 0.713 (unadjusted).</div></div><div><h3>Conclusion</h3><div>The RADAR score effectively predicts clinical risk and health status, offering a practical tool for monitoring COPD and guiding clinical decisions.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 28-34"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exhaled Volatile Organic Compounds as Potential Biomarkers of Exacerbation Risk in Asthma. 呼出的挥发性有机化合物作为哮喘恶化风险的潜在生物标志物。

IF 9.2 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-12-22 DOI: 10.1016/j.arbres.2025.12.003

Rocío Díaz-Campos, Miguel Jiménez-Gómez, Carolina Cisneros-Serrano, Andrea Trisán-Alonso, Antolín López-Viña, Rocío García-García, Irina Bobolea, José Javier Jareño-Esteban, Mª Ángeles Muñoz Lucas, Carlos Melero-Moreno

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Archivos De Bronconeumologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀